ARCHIVES

ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies

This article is from The Cancer Letter archive.

Vol. 38 No. 25 | June 22, 2012

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays Concepts For New Trials In Imaging, Intraoperative RT

June 14, 1985

As Amgen, Johnson & Johnson Battle Over Anemia Market, Medicare Enters The Fray

December 13, 2002

Reagan Signs Skins Cancer Resolution

March 29, 1985

Nixon National Cancer Conference Kicks Off

December 8, 2021

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010